PHATHOM PHARMACEUTICALS, INC.

PHAT ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2018
Revenue
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $20.0K
SG&A Expense $1.2M
Operating Income $-1.2M
Operating Margin
Interest Expense $13.0K
Pretax Income
Income Tax Expense $0
Net Income $-1.3M
Net Margin
EPS (Basic) $-0.21
EPS (Diluted) $-0.21
Shares Outstanding (Basic)
Shares Outstanding (Diluted)
Dividends Per Share
← Newer Page 2 of 2 Older →